论文部分内容阅读
Objective:To investigate the mechanism of Trilogy Detoxicating Therapy in treating patients with chronic renal failure(CRF).Methods:A total of 142 patients were assigned to the Trilogy Detoxicating Therapy group(the treatment group,82 patients)and the West medicine treatment group(the control group,60 patients).All of the patients were trealed with NovoNorm 1 mg and metformin hydrochloride tablets 0.15 g thrice per day for lowering the blood glucose,as well as Perindopril 4 mg twice daily for lowering blood pressure,recombinant human erythropoietin 2000 U and a hypodermic injection thrice a week for rectifying anemia,30 days as one course of treatment,and all patients were treated for two courses.Patients in the treatment group were treated with the dialysis and skin dialysis fumigationl in addition to the aforementioned drugs.Parameters observed and recorded in the study included renal function[serum creatinine(SCr),blood urea nitrogen(BUN)],blood lipids[triglyceride(TG),total cholesterol(TC),low-density lipoprotein C(LDL-C),high-density lipoprotein C(HDL-C)],plasma total protein(TP),hemoglobin(Hb),serum interleukin-6(IL-6),and tumor necrosis factor-α(TNF-α)before and after the treatment.Results:After two courses of treatment,the levels of SCr,BUN,TG,TC,LDL-C,serum IL-6 and TNF-α decreased significantly,meanwhile HDL-C increased in the treatment group(P＜0.05 or P＜0.01).In contrast,no obvious changes of the above mentioned items occurred in the control group.In both groups,the Ievels of TP and Hb were significantly elevated(P＜0.05 0r P＜0.01),but the changes were more obvious in the treatment group(P＜0.01).Conclusion:Trilogy Detoxicating Therapy played a therapeutic role on patients with CRF possibly through lowering the levels of blood lipids.serum IL-6 and TNF-α.